[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627026":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":30,"responsibleParty":46,"collaborators":19,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":19,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":19,"enrollmentInfo":57,"targetDuration":19,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":68,"overallStatus":32,"whyStopped":19,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Tungs' Taichung Metroharbour Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Multispecies synbiotic","EXPERIMENTAL","Participants will receive Renobiome multispecies synbiotic containing 30 billion CFUs per capsule, including strains of Lactobacillus rhamnosus (strain ID pending), Lactobacillus salivarius LS 159, Lactobacillus pentosus LPE 588, and Lactococcus lactis LL 358.\n\n* Dose: One capsule twice daily (morning and evening), with or without food, taken with room-temperature water.\n* Storage: Capsules to be kept below 25°C, in a dry, light-protected environment.",[13],"Dietary Supplement: Multispecies Synbiotic Supplementation",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DIETARY_SUPPLEMENT","Multispecies Synbiotic Supplementation",[9],null,[21,26],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Paik Seong Lim, PhD","CONTACT","+886935045292","jamespslim@gmail.com",{"name":27,"role":23,"phone":28,"phoneExt":19,"email":29},"Ming Ying Wu, MS\u002FMSc","+886933682221","ying5430@gmail.com",[31],{"facility":5,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Taichung","Wuqi District","435","Taiwan","TW",{"type":39,"coordinates":40},"Point",[41,42],120.6839,24.1469,{"lat":42,"lon":41},[45],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},{"type":47,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100627026","alterations-of-gut-derived-uremic-toxins-and-microbiome-metabolites-by-multispecies-synbiotic-100627026",false,"NCT07443280","Alterations of Gut Derived Uremic Toxins and Microbiome Metabolites by Multispecies Synbiotic","Alterations of Gut Derived Uremic Toxins and Microbiome Metabolites by Multispecies Synbiotic Supplementation in Hemodialysis Patients","Inclusion Criteria:\n\n* Adults aged 18 years or older receiving maintenance hemodialysis patients for at least 3 months\n\nExclusion Criteria:\n\n1. Use of probiotic supplements within the last month;\n2. Hospitalization within the past month for acute infections or CKD-related complications;\n3. History of major intestinal surgeries (gastrectomy, cholecystectomy; appendectomy allowed);\n4. Presence of viral hepatitis, liver cirrhosis, active malignancy, advanced congestive heart failure, or thyroid disorders;\n5. Use of antibiotics or immunosuppressive therapy within the preceding three months.","ALL","18 Years",{"count":58,"type":59},30,"ESTIMATED","INTERVENTIONAL",[62],"NA","Patients with chronic kidney disease (CKD) undergoing maintenance hemodialysis frequently exhibit significant gut microbiota dysbiosis and increased intestinal permeability. These alterations enable the translocation of endotoxins and gut-derived uremic toxins-such as indoxyl sulfate and p-cresyl sulfate-into the systemic circulation, exacerbating systemic inflammation, elevating cardiovascular risk, and accelerating disease progression.\n\nMultispecies synbiotic supplementation has emerged as a promising intervention to restore gut microbial equilibrium, strengthen intestinal barrier function, and reduce the systemic load of harmful microbial metabolites. Through modulation of inflammatory pathways and reduction of circulating uremic toxins, synbiotic hold potential to improve clinical outcomes in this vulnerable population.\n\nAlthough preclinical and some clinical evidence suggests benefits of probiotic therapy, comprehensive clinical trials specifically examining multispecies synbiotic effects on gut inflammatory markers, gut derived metabolite profiles, and uremic toxin levels in hemodialysis patients remain limited. This pilot study aims to address this gap by investigating the biological and clinical effects of a 12-week multispecies regimen in adult maintenance hemodialysis patients.",[65,66,67],"Symbiotic","Uremic Toxins","Gut -Microbiota",[69,70,71,72],"multispecies synbiotic","uremic toxins","gut microbiome","hemodialysis patients","2026-06-01",{"date":75,"type":76},"2026-06-03","ACTUAL",{"date":78,"type":76},"2026-05-04",{"date":80,"type":59},"2026-12-31",{"name":5,"class":6},1]